The leading malaria vaccine, RTS,S/AS01 which achieves up to 50% efficacy, appears to work primarily through the induction of high levels of antibodies against the circumsporozoite protein (CS) to block infection of hepatocytes [43]. The gene discussed is CS; the disease is infection.